Biomm S.A. (BVMF:BIOM3)

Market Cap	951.31M
Revenue (ttm)	143.94M
Net Income (ttm)	-71.89M
Shares Out	126.84M
EPS (ttm)	-0.58
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,100
Average Volume	38,135
Open	7.61
Previous Close	7.50
Day's Range	7.58 - 7.71
52-Week Range	6.52 - 13.08
Beta	0.58
RSI	43.97
Earnings Date	Aug 14, 2025

About Biomm

Biomm S.A. operates as a biotechnology company in Brazil. The company offers AFREZZA, a human insulin inhalation powder; GHEMAXAN, an enoxaparina sodica; GLARGILIN, a glargine insulin; WOSULIN R, a human insulin; WOSULIN N, an isophane insulin; HERZUMA, a trastuzumab; and CANETA LIFEPEN G PARA APLICACAO DE INSULINA. Biomm S.A. was founded in 2001 and is headquartered in Nova Lima, Brazil.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 130
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: BIOM3

Financial Performance

In 2024, Biomm's revenue was 142.91 million, an increase of 20.91% compared to the previous year's 118.19 million. Losses were -77.24 million, -4.81% less than in 2023.